|
|
| Low-Bioburden Powders For Terminal Sterilization | Article | Upperton Pharma Solutions | Low‑bioburden powders for reconstitution demand strict microbial control, advanced formulation, and specialized manufacturing, making CDMO expertise vital for modern biopharma. |
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | The question struck like a thunderbolt, writes chief editor Louis Garguilo. “Where are CDMOs going with all this?” asked Edward Ahn, CEO, Medipost, Inc., referring to the remarkable growth of some CDMOs. “When CDMOs aim to offer every service, capability, and the requisite capacities for an entire drug life cycle – from discovery to clinic to commercialization – what’s actually left for a biotech sponsor to do?” A forward discussion on an evolving outsourcing dynamic. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| Navigating High-Potency OSD Manufacturing | Article | Recipharm AB | Learn how containment strategy, process design, and early risk‑based decisions influence operator protection, compliance, and long‑term manufacturing success as potency levels continue to rise. |
|
|
| From Powder To Particles With Jet Milling | Webinar | Lonza | Gain valuable insights into the jet milling process and Quality by Design approach for inhalation drug delivery and their potential applications in drug development. |
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
